Payment overview · 2025
General Payments
$964.26
74 reported records · 17 companies
Healthcare provider profile · identity verified
Christina D Webb, MD
Allopathic & Osteopathic Physicians|Family Medicine · SCOTT DEPOT, WV · NPI 1801000633
Verified facts
What the public records show
CMS Open Payments records show Christina D Webb, MD received $964.26 in general payments during 2025 across 74 reported records.
ABBVIE INC. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $239.61 | 24.9% | 32 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $157.65 | 16.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.14 | 13.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.69 | 6.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.92 | 4.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.60 | 4.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.39 | 4.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.06 | 4.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.46 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.65 | 3.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.30 | 3.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.85 | 2.2% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $20.22 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.35 | 1.9% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $17.58 | 1.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.27 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.52 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $964.26 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $157.65 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $123.39 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.22 | 19 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.97 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.81 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 318 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 62 |
| Omeprazole | Omeprazole | 260 | 72 |
| Lisinopril | Lisinopril | 208 | 61 |
| Metformin Hcl | Metformin Hcl | 184 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 56 |
| Gabapentin | Gabapentin | 151 | 30 |
| Alprazolam | Alprazolam | 147 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 44 |
| Montelukast Sodium | Montelukast Sodium | 141 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 52 |
| Lorazepam | Lorazepam | 112 | 19 |
| Losartan Potassium | Losartan Potassium | 109 | 37 |
| Ezetimibe | Ezetimibe | 104 | 26 |
| Furosemide | Furosemide | 100 | 35 |
| Eliquis | Apixaban | 94 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 29 |
| Sertraline Hcl | Sertraline Hcl | 94 | 27 |
| Famotidine | Famotidine | 93 | 31 |
| Potassium Chloride | Potassium Chloride | 91 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 27 |
| Clonidine Hcl | Clonidine Hcl | 80 | 24 |
| Meloxicam | Meloxicam | 80 | 23 |
| Buspirone Hcl | Buspirone Hcl | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 29 |
| Alendronate Sodium | Alendronate Sodium | 74 | 24 |
| Allopurinol | Allopurinol | 74 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 15 |
| Fluconazole | Fluconazole | 68 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 18 |
| Pregabalin | Pregabalin | 66 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 17 |
| Ozempic | Semaglutide | 62 | 18 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Simvastatin | Simvastatin | 55 | 17 |
| Methylprednisolone | Methylprednisolone | 49 | 34 |
| Ibuprofen | Ibuprofen | 48 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 15 |
| Ondansetron Odt | Ondansetron | 47 | 12 |
| Promethazine Hcl | Promethazine Hcl | 47 | 11 |
| Trazodone Hcl | Trazodone Hcl | 47 | 15 |
| Mounjaro | Tirzepatide | 46 | 11 |
| Aripiprazole | Aripiprazole | 45 | 13 |
| Valacyclovir | Valacyclovir Hcl | 45 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Jardiance | Empagliflozin | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 13 |
| Celecoxib | Celecoxib | 38 | 13 |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 35 | 27 |
| Prazosin Hcl | Prazosin Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Bupropion Xl | Bupropion Hcl | 34 | 11 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 11 |
| Azelastine Hcl | Azelastine Hcl | 31 | 16 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Nystatin | Nystatin | 29 | 18 |
| Baclofen | Baclofen | 28 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Glipizide | Glipizide | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | 12 |
| Atenolol | Atenolol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Colchicine | Colchicine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $964.26 · 74 records | ABBVIE INC. | CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, FANAPT, GARDASIL 9, GEMTESA, KEVEYIS, Korlym, MOUNJARO, NEXPLANON, Ozempic, QULIPTA, REXULTI, Rybelsus, SLYND, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error